SCHEMBL1290972

SCHEMBL1290972

O=C(O)Nc1ccc(Oc2ccc([N+](=O)[O-])cn2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPB1 P04792 1/20 0.63
MAPT P10636 7/20 0.58
MEN1 O00255 6/20 0.58
KMT2A Q03164 6/20 0.58
NPSR1 Q6W5P4 2/20 0.57
RAB9A P51151 3/20 0.56
MAPK1 P28482 2/20 0.56
NPC1 O15118 2/20 0.56
MYOC Q99972 1/20 0.56
GAA P10253 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
PABPC1 P11940 2/20 0.53
POLB P06746 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.50
HPGD P15428 2/20 0.50
ALDH1A1 P00352 3/20 0.49
LMNA P02545 2/20 0.49
HTT P42858 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
PPARG P37231 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1290970 1.00 HSPB1 (0.63) HSPB1MAPTMEN1KMT2ANPSR1
SCHEMBL21628069 0.87 HSPB1 (0.60) HSPB1MAPTMEN1KMT2ANPSR1
SCHEMBL11685383 0.86 HSPB1 (0.59) HSPB1MAPTMEN1KMT2ANPSR1
SCHEMBL2858921 0.85 HSPB1 (0.54) HSPB1MAPTMEN1KMT2ANPSR1
SCHEMBL2858917 0.85 HSPB1 (0.54) HSPB1MAPTMEN1KMT2ANPSR1
SCHEMBL23797981 0.84 HSPB1 (0.55) HSPB1MAPTMEN1KMT2ANPSR1
SCHEMBL30391879 0.83 HSPB1 (0.55) HSPB1MAPTMEN1KMT2ANPSR1
SCHEMBL4690573 0.83 MEN1 (0.79) HSPB1MAPTMEN1KMT2ANPSR1
SCHEMBL20932230 0.83 HSPB1 (0.82) HSPB1MAPTMEN1KMT2ANPSR1
SCHEMBL2851303 0.82 HSPB1 (0.49) HSPB1MAPTMEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230139808-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-05-04 US disclosed
US-20210017134-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-01-21 US disclosed
US-20200031773-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-01-30 US disclosed
US-20180265471-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-09-20 US disclosed
US-20170298023-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMA CO LTD (JP) 2017-10-19 US disclosed
US-20150105432-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. 2015-04-16 US disclosed
US-8946437-B2 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-02-03 US disclosed
EP-2624833-B1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMA CO LTD (JP) 2014-12-10 EP disclosed
US-20130267565-A1 4- (METHYLAMINOPHENOXY) PYRDIN -3- YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-10-10 US disclosed
EP-2624833-A1 4- (METHYLAMINOPHENOXY) PYRDIN- 3 - YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER Otsuka Pharmaceutical Co., Ltd. (JP) 2013-08-14 EP disclosed
US-20120238750-A1 AROMATIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2012-09-20 US disclosed
WO-2012046825-A1 4- (METHYLAMINOPHENOXY) PYRDIN- 3 - YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105432-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER HCCS, IDH2, GLS2 HSPB1 2515/4885MAPT 4356/4885MEN1 617/4885
US-20230139808-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER HCCS, IDH2, MDH2 HSPB1 2540/4885MAPT 4428/4885MEN1 639/4885
US-20130267565-A1 4- (METHYLAMINOPHENOXY) PYRDIN -3- YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER HCCS, MDH2, IDH2 HSPB1 2425/4885MAPT 4342/4885MEN1 616/4885
US-20120238750-A1 AROMATIC COMPOUND CBR1, CBR3, CYP1A1 HSPB1 3924/4885MAPT 4315/4885MEN1 1020/4885
US-20180265471-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER HCCS, GLS2, IDH2 HSPB1 2510/4885MAPT 4358/4885MEN1 619/4885
US-20170298023-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER IDH2, MDH2, HCCS HSPB1 2507/4885MAPT 4336/4885MEN1 599/4885
US-20200031773-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER HCCS, GLS2, IDH2 HSPB1 2510/4885MAPT 4358/4885MEN1 619/4885
US-20210017134-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER HCCS, GLS2, IDH2 HSPB1 2510/4885MAPT 4358/4885MEN1 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.